-----------|-----------|--------|----------------|
| Dasatinib + Quercetin | Tyrosine kinase inhibition + antioxidant | BCL-2 family, p53 | Phase II trials for ADMorsch R, et al. (2021) |
| Navitoclax | BCL-2 family inhibitor | BCL-xL, BCL-W, BCL-2 | PreclinicalBussian TJ, et al. (2018) |
| Fisetin | Flavonoid, mTOR inhibition | Multiple pathways | Phase II completedRichardson RB, et al. (2020) |
| Rapamycin | mTOR inhibition | Senescence maintenance | Approved, repurposing potentialKeren-Shaul H, et al. (2017) |
Dasatinib + Quercetin (D+Q): The most studied senolytic combinationPereira JB, et al. (2022):
Senostatic drugs suppress the harmful secretions of senescent cells without killing themCui H, et al. (2022):
mTOR Inhibitors:
JAK Inhibitors:
NF-κB Pathway Blockers:
Other Approaches:
Targeting the immune consequences of senescenceCampisi J (2013):
Exercise: Reduces senescent cell burdenZhang G, et al. (2020)
Dietary Interventions:
Sleep Optimization: Sleep cleanses the brain of senescent cells and toxic metabolitesFreund A, et al. (2012)
Postmortem Brain Studies:
Clinical Trials:
Mouse Models:
Single-cell technologies: Mapping senescence across cell typesCoppe JP, et al. (2010)
Senolytics delivery: Targeted approaches to cross the BBBNCT04629495 (2020)
Combination therapies: Senolytics + traditional AD therapiesCanakinumab in Alzheimer''s disease: ongoing tr... (2022)
Biomarker development: Circulating senescent cell biomarkers predict AD progressionJones M, et al. (2025)